Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
has a consensus price target of $28.29 based on the ratings of 8 analysts. The high is $61 issued by Baird on July 28, 2023. The low is $16 issued by Canaccord Genuity on July 12, 2024. The 3 most-recent analyst ratings were released by Barclays, Barclays, and BTIG on February 5, 2025, January 9, 2025, and October 17, 2024, respectively. With an average price target of $26.67 between Barclays, Barclays, and BTIG, there's an implied 42.22% upside for from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for (:INMD) was reported by Barclays on February 5, 2025. The analyst firm set a price target for $29.00 expecting INMD to rise to within 12 months (a possible 54.67% upside). 14 analyst firms have reported ratings in the last year.
The latest analyst rating for (:INMD) was provided by Barclays, and maintained their overweight rating.
There is no last upgrade for
The last downgrade for happened on July 23, 2024 when Jefferies changed their price target from $21 to $19 for .
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of , and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for was filed on February 5, 2025 so you should expect the next rating to be made available sometime around February 5, 2026.
While ratings are subjective and will change, the latest (INMD) rating was a maintained with a price target of $26.00 to $29.00. The current price (INMD) is trading at is $18.75, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.